- Report
- January 2025
- 132 Pages
Global
From €858EUR$950USD£734GBP
- Report
- April 2024
- 132 Pages
Global
From €858EUR$950USD£734GBP
- Report
- November 2021
- 747 Pages
Global
From €3614EUR$4,000USD£3,090GBP
- Book
- November 2024
- 464 Pages
- Book
- March 2024
- 496 Pages
- Book
- April 2023
- 2000 Pages
- Book
- August 2022
- 320 Pages
- Book
- December 2018
- 784 Pages
- Book
- July 2018
- 360 Pages
- Book
- April 2018
- 312 Pages
- Book
- March 2017
- 2008 Pages

Cancer Immunotherapy is a type of Immune Disorders Drugs that uses the body's own immune system to fight cancer. It works by stimulating the body's natural defense system to recognize and attack cancer cells. This type of therapy is used to treat a variety of cancers, including melanoma, lymphoma, and leukemia. It can also be used to treat other types of cancer, such as breast, lung, and colorectal cancer.
Cancer Immunotherapy is a rapidly growing field, with many new treatments being developed. It is an important part of the overall cancer treatment landscape, as it can provide a more targeted approach to treating cancer. It can also be used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes.
Some of the companies in the Cancer Immunotherapy market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are developing a range of treatments, including monoclonal antibodies, vaccines, and cell-based therapies. Show Less Read more